<DOC>
	<DOC>NCT00044278</DOC>
	<brief_summary>This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.</brief_summary>
	<brief_title>Pediatric Epilepsy Study in Subjects 1-24 Months</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>Inclusion criteria: Must have completed the OpenLabel Phase of protocol LAM20006 or meet criteria for LAMICTAL naive subjects as follows: A confident diagnosis of epilepsy. 4 or more partial seizures per month. current treatment with 1 or 2 antiepileptic drugs. Exclusion criteria: Has seizures not related to epilepsy. Has a surgically implanted and functioning vagal nerve stimulator. Has previously been treated with lamotrigine. Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the ketogenic diet. Use of experimental medication within 30 days of enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>pediatric</keyword>
	<keyword>partial seizures</keyword>
</DOC>